Please login to the form below

Not currently logged in
Email:
Password:

Merck KGaA 'to promote' Stefan Oschmann to chief executive

Germanphamra company reportedly set to elevate him to the top job next year

Merck KGaA Stefan OschmannMerck KGaA is set to elevate its deputy chief executive Stefan Oschmann to replace chief executive Karl-Ludwig Kley, according to local reports.

Manager Magazin says the German pharma company plans to promote Oschmann next year, either after its annual general meeting in May 2016 or when Kley's contract expires in September.

But a Merck spokeswoman told Reuters that a decision on Kley's succession had not yet been made and that this would be a matter for the family-controlled group's board of partners.

Oschmann has been vice chairman of Merck's executive board since January and prior to this was responsible for Merck's Pharma business as Member of the Executive Board from 2011 to 2014.

Before joining Germany's Merck he worked for its namesake Merck & Co as the US company's president of emerging markets for Merck Sharp & Dohme (MSD), as its operations are known outside the US.

Prior to joining MSD Oschmann worked for the International Atomic Energy Agency IAEA from 1985 to 1987 and for the German Animal Health Federation (BfT) from 1987 to 1989.

26th March 2015

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....